Thrombophob

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Thrombophob

The foundational identity of Thrombophob is established by its active substance and its pharmaceutical classification, strictly defining what the preparation is, its composition, and its general purpose as a surface-acting treatment.


Quick Facts: Thrombophob Gel Identity

Property Description
Active ingredient Heparin Sodium (Heparin)
Form Gel (Cutaneous Preparation)
Pharmacological class Anticoagulant, Antithrombotic Agent
Common purpose To support blood flow and ease discomfort from minor venous congestion
Origin Derived from natural Glycosaminoglycan, manufactured for medicinal use

What is Thrombophob and What Pharmacological Class Does it Belong To?

Thrombophob Gel is a pharmaceutical specialty classified as an anticoagulant and antithrombotic agent, formulated as a cutaneous preparation for localized treatment. This medication is designed for topical administration, applied directly to the skin surface to exert its primary action in the superficial tissues. Thrombophob falls into the pharmacological class of anticoagulants because it directly affects the blood clotting process. Local heparin preparations are used to aid superficial circulatory issues, distinguishing them from systemic therapies. Its function is to provide a focused, local effect, placing it within the therapeutic category of surface-acting preparations designed to manage minor circulatory disturbances without influencing the body's overall systemic coagulation cascade.


Composition and Origin: Is Thrombophob Made of Heparin?

Yes, the sole active ingredient in Thrombophob Gel is Heparin Sodium, which is chemically classified as a sulfated polysaccharide and a glycosaminoglycan. The active substance within this single-ingredient product is manufactured and purified for medicinal use. The preparation is presented as a gel base, an aqueous-alcoholic vehicle specifically formulated for the efficient diffusion of the active substance into the superficial layers of the skin following topical administration. Topical application of Heparin is used to provide relief from localized inflammation and swelling associated with superficial venous issues. This characteristic supports its role in helping to ease localized discomfort, such as that experienced after extended periods of standing or minor impact.


What is the General Purpose of This Topical Anticoagulant?

The general purpose of this preparation is to utilize its local anticoagulant action to help manage minor venous congestion and support fluid blood flow. By promoting local anticoagulation, Thrombophob interferes with localized clotting factors in the targeted area, helping to inhibit the formation and growth of small blood clots (thrombi) near the skin surface. This mechanism is central to relieving general discomfort, heaviness, or tightness associated with minor, superficial circulatory disturbances without affecting the body's overall systemic clotting ability, thus supporting unhindered blood flow in the capillaries and superficial veins.

Regulatory References

  1. Heparin sodium on the WHO Essential Medicines List

What side effects are possible with Thrombophob?

Possible side effects and safety information

The safety profile of Thrombophob Gel is primarily characterized by effects localized to the skin, reflecting its topical administration as an anticoagulant agent. Regulatory classifications organize these effects based on the frequency reported in official documentation.


Adverse Reactions and Safety Categories

Classification Common Reactions Rare Reactions
Skin & Subcutaneous Tissue Disorders Redness (Erythema), Itching (Pruritus), Irritation, and a local burning sensation at the application site. Severe local Hypersensitivity reactions, including urticaria (hives) or generalized rash.
Hemorrhagic Effects Increased local tendency for bruising (hematoma) or small red spots (petechiae). Not typically reported for topical use due to minimal systemic absorption.

Safety Constraints and Special Populations

Official labeling defines specific constraints governing the use of the preparation, based on safety considerations for the active substance, Heparin Sodium.

  • Contraindications: The gel is contraindicated in individuals with known hypersensitivity or allergy to Heparin Sodium or any component of the formulation.
  • Application Restrictions: It must not be applied to open wounds, areas of active bleeding, broken skin, or mucous membranes.
  • Interaction Safety: The official label notes that concurrent use with systemic anticoagulant medications may increase the risk of localized hemorrhagic signs, such as bruising.
  • Data Limitations: Safety data is often noted as limited or unavailable in regulatory documents for the topical formulation's use during pregnancy or lactation, or in patients with severe renal or hepatic impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation for this topical formulation of Heparin Sodium states that no case of overdose has been reported so far. As an external cutaneous preparation, the risk of systemic overexposure is significantly limited.


Official Regulatory Statements

Feature Regulatory Documentation Status
Documented Overdose Cases None reported for the topical gel formulation.
Anticipated Systemic Risk The primary concern is hemorrhage or an increased bleeding tendency, the known severe outcome of systemic heparin overexposure.
Exposure-Related Factors Risk is noted if the product is used on large areas or concurrently with systemic anticoagulant products.

Required Emergency Actions

Due to the potential for systemic effects upon significant overexposure, the regulatory guidance is focused on managing the active substance, Heparin.

  • Seek immediate medical attention if any signs of unusual or severe bleeding occur. This is the regulator-mandated action for suspected systemic complications.
  • The effect of the active substance can be neutralised with protamine sulphate in an emergency setting.
  • Symptomatic and supportive treatment is the official general management approach for complications arising from overexposure.

These statements define the official protocol for the unlikely event of overexposure to the active substance, establishing the requirements for seeking urgent medical care.

Therapeutic Uses of Thrombophob

Quick Facts

  • Therapeutic Domain: Superficial vein inflammation and swelling
  • Primary Indications: Management of superficial thrombophlebitis and localized bruising
  • Therapeutic Action: Reduces swelling and aids in the resolution of blood clots near the skin surface

Thrombophob is a topical medication indicated for the management of certain localized circulatory conditions. Its primary use is in the treatment of superficial thrombophlebitis, a condition involving inflammation of a vein near the surface of the skin, often associated with the presence of a blood clot.

Therapeutic benefits focus on local relief and resolution of symptoms. The medication is used to reduce the swelling and tenderness associated with inflamed veins. It is also employed for the supportive management of superficial bruises (hematoma), where it may aid in the breakdown of blood collections beneath the skin. By promoting local circulation, the treatment helps to mitigate symptoms and supports the body's natural resolution processes in the affected area.

Thrombophob should be used strictly as directed by a healthcare professional.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Thrombophob?

Official regulatory documents define specific populations for whom the use of Thrombophob ointment is either strictly prohibited or requires medical oversight.


Populations Who Must Not Use the Medicine (Contraindications)

Individuals are formally contraindicated if they have a known hypersensitivity or allergy to the active substances, Heparin Sodium or Benzyl Nicotinate, or to any other components of the formulation. Application is also prohibited on open wounds, skin ulcers, broken skin, mucous membranes, or near the eyes.


Populations Requiring Conditional or Restricted Use

  • Pregnancy and Breastfeeding: Use is restricted and generally not recommended unless specifically advised by a doctor. This restriction is due to limited established human safety data, requiring the benefit to clearly outweigh any potential risk.
  • Pediatric Population: Use in children under 18 is advised only with caution and under medical supervision, as specific safety data for this age group may be limited.
  • Bleeding Disorders: Patients with pre-existing blood or bleeding disorders must use the medicine with caution, as directed by a healthcare professional, due to the anticoagulant activity of one of the active ingredients.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Thrombophob Gel (Heparin Sodium) is defined by its method of use as a topical cutaneous preparation for localized application. As confirmed by pharmacokinetic data cited in government regulatory documents, the systemic absorption of the active ingredient, Heparin, is minimal to negligible when applied to intact skin.

This minimal absorption results in clinically insignificant plasma levels, which is the regulatory basis for the absence of systemic drug-drug interaction warnings in the official prescribing information. Consequently, governmental sources do not cite known interactions with co-administered oral anticoagulants, antiplatelet agents, or other systemic medicines that could affect the body's overall coagulation cascade or metabolic pathways.

Official Interaction Structure

Interaction Type Regulatory Status for Topical Use
Systemic Drug-Drug Interactions None documented as clinically significant.
Metabolic (CYP/Transporter) Interactions None documented.
Food, Alcohol, or Herbal Interactions None documented.
Administration Timing Rules None documented; no required dose separation is specified.

The only constraint related to the drug's activity is a mandatory restriction regarding the application site. Official labeling requires that the gel must not be applied to open wounds, damaged skin, bleeding areas, or mucous membranes, which prevents potential local bleeding or irritation due to the product's intended anticoagulant action.

Mechanism of Action

The mechanism of action for Thrombophob, whose primary active component is Heparin Sodium, is strictly localized to the superficial tissues, focusing on modulating localized blood fluidity and inflammatory processes. The Heparin molecule does not achieve systemic concentrations sufficient for modulation of the body's global coagulation cascade.

Localized Activation of Antithrombin III

The primary mechanism involves the active substance, Heparin, functioning as a cofactor to dramatically enhance the activity of the body's natural protein, Antithrombin III ( AT III). This molecular interaction leads to the rapid inhibition of key clotting factors, specifically Factor Xa and Thrombin ( IIa), disrupting the final common pathway of coagulation in the superficial tissues. The resulting physiological effect is the localized inhibition of new thrombus formation or proliferation.

Modulation of Anti-Exudative Pathways

Beyond its role in blood fluidity, the mechanism involves the modulation of the inflammatory/exudative pathway by binding to and influencing various local enzymes and mediators. This action modulates the permeability of superficial capillary walls, limiting the excessive leakage of fluid and protein from the bloodstream into the surrounding subcutaneous tissue. This results in **decreased extravasation of fluid and protein, resulting in lower local tissue volume.***>>

Dosage and Administration Information

Thrombophob is a pharmaceutical preparation formulated as a gel, intended strictly for topical administration to the skin surface. Standard usage principles involve a consistent, localized application to the affected area.

The standard regimen for adults involves applying a thin layer of the gel to the entire affected area. The dosage is often quantified as a ribbon of gel, typically specified as up to 10 cm in length, which should be administered two to three times daily. This schedule is maintained consistently throughout the intended course of therapy.

The proper administration technique requires the gel to be applied only to clean, dry skin. The preparation must then be gently massaged into the application site until it is fully absorbed into the superficial tissues. Treatment is intended for a defined, short duration, commonly limited to a maximum of one to two weeks for superficial venous issues or up to ten days for acute swelling conditions, thereby structuring the overall treatment scope.

Regarding specific populations, the standard adult regimen is applicable to the elderly. However, a population restriction applies where the preparation is not recommended for use in children and adolescents up to 18 years of age due to a lack of sufficient clinical data for this group.

Recent Clinical Evidence

Recent Clinical Evidence

This section summarizes key findings from clinical studies that have investigated the combination ointment containing heparin sodium and benzyl nicotinate (e.g., Thrombophob). It describes the observations from research and does not offer clinical advice.


Efficacy and Outcome Studies

Clinical research, including a large prospective, observational, single-arm registry study (N=2002) conducted in India, examined the ointment’s use in patients with thrombophlebitis.

  • Symptom Changes: Studies reported differences compared to baseline across various markers of venous health. Compared to the initial assessment, patients showed reduced severity of phlebitis, shorter venous lesion lengths, and lower pain and tenderness scores by day 3 and day 7 of treatment.
  • Formulation Comparison: Other randomized controlled trials have focused on comparing different formulations of topical heparin. For example, some research comparing a topical heparin gel formulation (often used as a comparator product) against topical heparin solutions in preventing infusion-associated phlebitis found that the solution was associated with lower rates of phlebitis development.

Safety and Tolerability Research

The large registry study of 2002 patients also monitored the safety profile of the heparin sodium and benzyl nicotinate ointment. The research reported a low incidence of adverse effects among the participants. The overall tolerability of the treatment, as assessed by physicians, was rated as excellent or good in 99% of patients in this study.

  • Observed Side Effects: Very few patients experienced adverse effects (0.25% by day 3 and 0.05% by day 7) during the observational period. Local skin reactions, such as urticaria (hives) and erythema (redness), have been reported in case studies following application.

Frequently Asked Questions (FAQ)

Common questions about Thrombophob (FAQ)


Q: Does Thrombophob help with bruising?

Official regulatory information describes this preparation's indication in the management of superficial bruising (hematomas) and associated localized discomfort that may result from blunt injuries. Its general purpose is to support localized fluid blood flow beneath the skin's surface.


Q: Can Thrombophob be used for swelling?

The preparation is described in official documentation for supportive use in the management of acute swelling conditions and localized fluid build-up. This is related to its anti-exudative properties, which aim to modulate the permeability of superficial capillary walls and influence localized tissue volume.


Q: Is Thrombophob effective for varicose veins?

The preparation is indicated for use in superficial venous affections (vein-related issues), according to official information. This includes the localized management of discomfort and inflammation caused by conditions like thrombophlebitis, which are often associated with varicose veins.


Q: What is the general duration of treatment described for Thrombophob?

According to official regulatory guidance, the use of this preparation is generally intended for a defined, short period. Treatment duration is commonly specified as up to one to two weeks for localized superficial venous issues or a maximum of ten days when used for acute swelling conditions.


Q: Should I avoid direct sunlight while using Thrombophob?

The official precaution states that the product may increase skin sensitivity to UV rays (photosensitivity). Because of this, avoiding prolonged exposure to direct sunlight, sunlamps, or tanning beds on the treated area is advised in the labeling.


Q: Is Thrombophob available over the counter?

The regulatory classification of this product can differ significantly by country or jurisdiction. In many regions, the preparation may be classified as a medicine that does not require a prescription (Over-The-Counter or equivalent) for purchase.


Q: What is the difference between Thrombophob and other similar creams/gels?

The core differences are typically based on the product’s active ingredient(s) (e.g., Heparin Sodium versus other agents) and the formulation type (e.g., gel versus ointment or cream) as described in their respective regulatory profiles.


Q: How quickly can I expect Thrombophob to start working?

Official sources often state that the time to relief or onset of action can vary between individuals and is dependent on the specific condition being addressed. The preparation is intended for localized application and superficial action.


Q: Is it normal to feel a tingling sensation after applying Thrombophob?

The official list of commonly reported local side effects includes a local burning sensation, irritation, and redness at the application site. Because tingling is not explicitly listed, users should refer to the full list of recognized side effects documented in the official labeling.


Q: How is Thrombophob classified by regulatory bodies?

Regulatory bodies officially classify this preparation within the therapeutic class of Anticoagulant, Antithrombotic Agents. This classification is specific to its function as a topical cutaneous preparation designed for localized action on the skin.


Q: Does Thrombophob come in different strengths or formulations?

The active substance in Thrombophob is produced in various forms, such as Gel or Ointment, which may be available in different markets. These formulations may also contain the active substance in varying concentrations, depending on the manufacturer.


Q: Is Thrombophob used for internal hemorrhoids?

Official indications and usage statements for this topical gel generally do not list internal hemorrhoids as a recognized or approved use. The product's application is primarily limited to external, superficial skin areas.


Q: Do I need a prescription to buy Thrombophob in all countries?

No. The regulatory requirement for obtaining a prescription to purchase this topical medicine varies significantly by country or region. This difference is based on the local health authority's scheduling of topical heparin products.


Q: Can I apply Thrombophob to large areas of my body?

Regulatory warnings advise caution when the product is applied to large areas of the skin, particularly when used in situations where other systemic anticoagulant medications are involved. This advisory is based on the theoretical potential for an increased localized bleeding risk.


Q: Does the official guidance mention any specific dietary restrictions while using Thrombophob?

Official regulatory documents and labeling generally do not cite specific food or dietary restrictions that must be followed while using this preparation. This is attributed to the minimal amount of the active ingredient that is absorbed systemically (into the bloodstream).


Q: What is the shelf life of Thrombophob after opening the tube?

Official documentation for certain topical heparin formulations defines a specific period for 'in-use stability.' For some versions, the documented shelf life is defined as 24 weeks (or a similar defined period) after the tube has been opened for the first time.


Q: Can I use Thrombophob if I have a history of allergies to other topical medicines?

Official documentation states that the preparation is strictly contraindicated if a known hypersensitivity or allergy exists to the active ingredient (Heparin Sodium) or to any other component, including inactive ingredients (excipients), in the formulation.


Q: Are there any studies comparing the gel vs. cream formulation of Thrombophob?

Clinical literature and regulatory documents have examined the safety and efficacy of various topical heparin solutions and gels in studies. Research often uses different formulations as comparator products to assess their relative absorption and localized effects.


Q: What information does the patient leaflet for Thrombophob typically contain?

The patient information leaflet is a mandatory regulatory document. It must include information on what the medicine is used for, how to use it, potential side effects, contraindications (who must not use it), and mandatory storage and disposal instructions.

How should Thrombophob be stored and disposed of?

How to Store and Dispose of Thrombophob

This information reflects the mandatory requirements for storing and disposing of Thrombophob, as defined in official regulatory documents.

Mandatory Storage Conditions

Requirement Official Instruction
Temperature Store below 25 C
Protection Protect from heat and direct sunlight
Container Keep in the original container, tightly closed
Safety Keep out of the reach of children and pets

Disposal Guidelines

Thrombophob must not be used past the expiration date printed on the package. Any unused or expired medicine must be disposed of according to the instructions on the package or label. Do not dispose of this product with regular household waste unless explicitly instructed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Thrombophob found in:

A-Z Index: